Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Dyne Therapeutics has raised $200.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in June 2026.
Dyne Therapeutics's investors include Franklin Templeton, RA Capital Management, Wellington Management, Vida Ventures, Forbion Capital Partners.
Dyne Therapeutics is headquartered in Cambridge, United States.
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Dyne Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dyne Therapeutics — Funding & Investors." VCBacked, June 17, 2026, https://www.vcbacked.co/company/dyne-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Dyne Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/dyne-therapeutics
{{cite web |title=Dyne Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/dyne-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated